IGFLR3

IGF-1 LR3

No registered human study names IGF-1 LR3 as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains IGF-1 LR3. 10 papers naming it were published in the last ten years.

Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names IGF-1 LR3; the registry search is fuzzy, so every match is re-checked. None of this says whether IGF-1 LR3 works or is safe.

FDA status

Research only

Human studies

0

Furthest phase

Papers, 10 yr

10

Readership

2,390

monthly average, Feb–Jul 2026

Tracking since 2026-07-29 · About this data

What has actually been tested in humans

X

No registered human study

0

Registered human studies

None

No FDA-approved product contains it

No study of IGF-1 LR3 in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.

What IGF-1 LR3 is, and what it has been studied for

IGF-1 LR3 is tracked here.

No registered trial names IGF-1 LR3 as an intervention, so there is no condition it has been formally studied in. It does have a literature: 10 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.

Is anyone studying IGF-1 LR3?

Papers published each year that name IGF-1 LR3 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.

0123417181920212223242526
Vertical axis: papers published that year. Bar for 2026 is hatched because that year is still running.
Publications and trials naming IGF-1 LR3, by year
YearPublicationsTrials startedComplete year
201700Yes
201800Yes
201900Yes
202010Yes
202120Yes
202210Yes
202320Yes
202420Yes
202530Yes
202610No

10 papers between 2017 and 2026. A paper counts when “IGF-1 LR3” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.

Published research on IGF-1 LR3

10 indexed papers name IGF-1 LR3 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.

  1. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris

    Lu Z, Liu N, Huang H, et al.Applied microbiology and biotechnology2023

    PMID 3726145510.1007/s00253-023-12606-0

  2. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep

    White A, Stremming J, Wesolowski SR, et al.American journal of physiology. Endocrinology and metabolism2025

    PMID 3967994310.1152/ajpendo.00259.2024

  3. Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets

    White A, Stremming J, Brown LD, et al.Journal of developmental origins of health and disease2023

    PMID 3711475710.1017/S2040174423000090

  4. Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration

    Yavuz E, Sağır MS, Ercan A, et al.International journal of biological macromolecules2025

    PMID 4101537010.1016/j.ijbiomac.2025.147888

  5. Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep

    Jonker SS, Giraud GD, Chang EI, et al.FASEB journal : official publication of the Federation of American Societies for Experimental Biology2020

    PMID 3257385210.1096/fj.202000215R

  6. IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus

    Stremming J, Heard S, White A, et al.American journal of physiology. Endocrinology and metabolism2021

    PMID 3342705110.1152/ajpendo.00453.2020

  7. Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect

    White A, Stremming J, Boehmer BH, et al.American journal of physiology. Endocrinology and metabolism2021

    PMID 3393823610.1152/ajpendo.00623.2020

  8. Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes

    Sundgren NC, Giraud GD, Schultz JM, et al.American journal of physiology. Regulatory, integrative and comparative physiology2003

    PMID 1294703010.1152/ajpregu.00232.2003

Collected 2026-08-02from PubMed, phrase-matched on “IGF-1 LR3” in title and abstract. Run the same search.

Reading on this compound

All articles

PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.

Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.